

2026 Meeting on Transplant and Cellular Therapy for Immunological Disorders Session Information

Georg Schett, MD - Uniklinikum Erlangen (Germany)

Resetting the Immune System by Deep B Cell Depletion

An overview of deep B-cell depletion as a promising therapeutic strategy for immune reset in autoimmune diseases, including current evidence and future perspectives.

Nasheed Hossain, MD - University of Pennsylvania

B-cell Reset - the Rationale for B-cell Depletion in Autoimmune Diseases

An overview of how B-cell depletion induces a therapeutic response in autoimmune diseases. This will be tied into the rationale for considering cellular immunotherapies (CAR T cell therapy) for various antibody driven autoimmune diseases.

Everett Meyer, MD, PhD - Stanford University

Hematopoietic Stem Cell Transplantation as a Treatment Strategy for Autoimmune Conditions and Immune Tolerance: Autologous or Allogeneic?

Provide a summary of the potential role of hematopoietic stem cell transplantation for the treatment of autoimmune disorders and immune tolerance induction.

Amanda Piquet, MD - University of Colorado Anschutz

CAR T-Cell Therapy in Stiff Person Syndrome

This session will review the scientific rationale for CD19-directed CAR T-cell therapy in stiff person syndrome (SPS) and present the primary results from the pivotal KYSA-8 trial of mivocabtagene autoleucel (miv-cel; KYV-101). Attendees will gain an overview of the efficacy, safety, and durability of response observed with this novel therapeutic approach, as well as its potential to transform the treatment landscape for patients with refractory SPS and inform the future of cell-based therapies in autoimmune neurology.

Chafic Karam, MD - University of Pennsylvania

Chimeric Antigen Receptor (CAR) T-Cell Therapy in Myasthenia Gravis (MG)

This session will review the rationale for chimeric antigen receptor (CAR) T-cell therapy in myasthenia gravis (MG) and discuss the current CAR-T-based therapeutic strategies under investigation for patients with MG.

Dinesh Khanna, MD, MS - University of Michigan

Cellular Therapies in Systemic Sclerosis and Inflammatory Myopathy

Discuss latest efficacy and safety data in SSc and IIM, ongoing Phase 1/2 clinical trials, and present ongoing translational research in these diseases

Jeffrey Miller, MD - Masonic Cancer Center at the University of Minnesota

Developing NK Cell Therapeutics: Learning From Cancer to Treat Autoimmune Disease

There have been significant advances in cell therapy to treat B-cell malignancies. These have adapted to autoimmune settings spanning a broad spectrum of disease. NK cell may be optimal for this because they mediate less CRS than T cells. Both off-the-shelf NK cell therapeutics and accomplishing th8s goal with engagers will be discussed.

Jeffrey Cohen, MD - Cleveland Clinic

AHSCT and CAR-T for Neurologic Conditions

AHSCT and CAR-T for Neurologic Conditions - This session will review the current status of cell therapy for neurologic conditions.

Jeffrey Cohen, MD - Cleveland Clinic

Cell Therapy in the Community

This session will review practical aspects of implementing cell therapy.

Keith Sullivan, MD - Duke University

CAR-T for Rheumatologic Conditions- Introduction

There are over 100 rheumatologic and neurologic autoimmune diseases which cause considerable morbidity and mortality. Cellular therapies are a breakthrough offering the potential for durable improvement of chronic immunosuppression. This session will review the basic science of

autoimmune diseases and the mechanisms, indications and current outcomes of cell therapies for these disorders.

William Robinson, MD, PhD - Stanford University

Mechanisms of Action of AHSCT and CAR T

CAR T cell and T cell engager bi-specific antibodies are emerging as transformative therapeutics for autoimmune disease, and this session will provide an overview of progress to date and opportunities ahead.

Ran Reshef, MD, MSc - Columbia University Irving Medical Center

The Emerging Role of CAR-T in SLE and Lupus Nephritis

This session explores the transformative potential of CAR-T cell therapy as a strategy for deep immune reset in SLE and lupus nephritis. We will review recent clinical data, evaluate renal and systemic outcomes in patients with severe or refractory disease, and discuss the practical considerations of bringing oncology-derived cellular therapies into rheumatology practice.

Navneet Majhail, MD, MS, FASTCT - Sarah Cannon Transplant and Cellular Therapy Network

Bringing Cellular Therapy Into the Community